初期アルツハイマー病(ALTITUDE-AD)の参加者における静脈内 ACU193 の有効性と安全性を評価する研究 (ALTITUDE-AD)
初期アルツハイマー病における静脈内 ACU193 の有効性と安全性を評価するための第 2/3 相二重盲検ランダム化プラセボ対照適応設計試験
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Carlsbad、California、アメリカ、92011-4219
- The Neurology Center of Southern California - Carlsbad
-
Fullerton、California、アメリカ、92835
- Neurology Center of North Orange County
-
Irvine、California、アメリカ、92614
- Irvine Medical Research
-
Long Beach、California、アメリカ、90804
- Healthy Brain Research
-
Santa Ana、California、アメリカ、92705
- Syrentis Clinical Research
-
Sherman Oaks、California、アメリカ、91403-2131
- CenExel - California Neuroscience Research Medical Group, Inc (CNR)
-
-
Connecticut
-
Norwalk、Connecticut、アメリカ、06851-4903
- Research Center for Clinical Studies, LLC
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、22031
- Re:Cognition Health - Fairfax
-
-
Florida
-
Atlantis、Florida、アメリカ、33462
- JEM Research Institute
-
Bradenton、Florida、アメリカ、34205
- Bradenton Research Center
-
Coral Gables、Florida、アメリカ、33135
- Gil Fernandez-Yera, MD, PA
-
Delray Beach、Florida、アメリカ、33445
- Brain Matters Research
-
Homestead、Florida、アメリカ、33032
- Coral Clinical Research
-
Lady Lake、Florida、アメリカ、32159
- K2 Medical Research - Villages
-
Miami、Florida、アメリカ、33126
- Finlay Medical Research
-
Naples、Florida、アメリカ、34105-8522
- Aqualane Clinical Research
-
Ocala、Florida、アメリカ、34470
- Ocala Health - Family Care Specialists - Ocala I
-
Port Orange、Florida、アメリカ、32127
- Progressive Medical Research
-
Stuart、Florida、アメリカ、34997
- Alzheimer's Research and Treatment Center - Stuart
-
Tampa、Florida、アメリカ、33607
- K2 Medical Research - Tampa
-
The Villages、Florida、アメリカ、32162
- Charter Research - Lady Lake
-
Wellington、Florida、アメリカ、33414
- Alzheimers Research and Treatment Center - Wellington
-
Winter Park、Florida、アメリカ、32789
- Conquest Research
-
Winter Park、Florida、アメリカ、32792
- Charter Research - Winter Park
-
-
Georgia
-
Columbus、Georgia、アメリカ、31909
- Columbus Memory Center
-
Decatur、Georgia、アメリカ、30030
- CenExel - iResearch Atlanta
-
-
Illinois
-
Northbrook、Illinois、アメリカ、60640
- Office of Jeffrey S. Ross, MD
-
-
Massachusetts
-
Newton、Massachusetts、アメリカ、02459
- Boston Center for Memory
-
-
Mississippi
-
Hattiesburg、Mississippi、アメリカ、39401-7246
- Hattiesburg Clinic - Memory Center
-
-
New Hampshire
-
Portsmouth、New Hampshire、アメリカ、03801
- ActivMed Practices and Research
-
-
New Jersey
-
Springfield、New Jersey、アメリカ、07081
- The Cognitive and Research Center of New Jersey
-
Toms River、New Jersey、アメリカ、08755
- CenExel - Advanced Memory Research Institute of NJ
-
-
New York
-
Albany、New York、アメリカ、12208
- Neurological Associates of Albany
-
-
North Carolina
-
Matthews、North Carolina、アメリカ、28105
- AMC Research
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic
-
-
Oregon
-
Portland、Oregon、アメリカ、97210
- Summit Research Network
-
-
Pennsylvania
-
Abington、Pennsylvania、アメリカ、19001
- Abington Neurological Associates
-
Norristown、Pennsylvania、アメリカ、19462
- Keystone Clinical Research
-
-
Rhode Island
-
East Providence、Rhode Island、アメリカ、02914
- Rhode Island Mood and Memory
-
-
Tennessee
-
Cordova、Tennessee、アメリカ、38018
- Neurology Clinic. P.C
-
Knoxville、Tennessee、アメリカ、37920-1511
- The Alliance for Multispecialty Research LLC (AMR)
-
-
Texas
-
Austin、Texas、アメリカ、78757
- Senior Adult Specialty Research
-
Beaumont、Texas、アメリカ、77702
- Gadolin Research, LLC
-
Dallas、Texas、アメリカ、75231
- Kerwin Medical Center
-
-
-
-
-
Bristol、イギリス
- Re:Cognition Health - Bristol
-
-
Greater London
-
London、Greater London、イギリス
- Re:Cognition Health - London
-
London、Greater London、イギリス
- St. Pancras Clinical Research Ltd.
-
-
Hampshire
-
Winchester、Hampshire、イギリス
- Re:Cognition Health - Winchester
-
-
Lanarkshire
-
Motherwell、Lanarkshire、イギリス
- Neuroclin Glasgow
-
-
Lancashire
-
Preston、Lancashire、イギリス
- Panthera Bio-Partners - Preston
-
-
Surrey
-
Guildford、Surrey、イギリス
- Re:Cognition Health - Guildford
-
-
Yorkshire
-
Sheffield、Yorkshire、イギリス
- Panthera Biopartners - Sheffield
-
-
-
-
British Columbia
-
Kelowna、British Columbia、カナダ
- Okanagan Clinical Trials
-
-
Ontario
-
Ottawa、Ontario、カナダ
- Hippocampe d/b/a Ottawa Memory Clinic
-
Toronto、Ontario、カナダ
- Toronto Memory Program (TMP) (Neurology Research Inc.)
-
-
Quebec
-
Greenfield Park、Quebec、カナダ
- MoCA Research and Innovations
-
-
-
-
-
Barcelona、スペイン
- Fundacio ACE
-
Donostia / San Sebastian、スペイン
- Policlínica Gipuzkoa
-
Getxo、スペイン
- Cae Oroitu
-
Madrid、スペイン
- Hospital Ruber
-
Seville、スペイン
- Hospital Victoria Eugenia
-
Valencia、スペイン
- Hospital Universitari i Politècnic La Fe
-
-
Barcelona
-
Sant Cugat del Vallès、Barcelona、スペイン
- Hospital Universitari General de catalunya
-
-
Zaragoza
-
Cuarte de Huerva、Zaragoza、スペイン
- Fundacion Neuropolis - Hospital Viamed Montecanal
-
-
-
-
-
Berlin、ドイツ
- Charité - Universitaetsmedizin Berlin
-
Cologne、ドイツ
- University Hospital of Cologne
-
Mannheim、ドイツ
- Zentralinstitut für seelische Gesundheit
-
Munich、ドイツ
- Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Body weight of at least 30 kilograms (kg) (66 pounds [lbs]) and no more than 160 kg (352 lbs) at Screening
-
Must consent to apolipoprotein E4 (APOE4) genotype status assessment
-
Must meet all of the following criteria
- National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or probable AD
- Screening score between 22 and 30 (inclusive) on the Mini-Mental State Examination (MMSE)
- Screening score of 0.5 or 1.0 on the Clinical Dementia Rating Global Score (CDR-GS) and Screening score ≥0.5 on the CDR Memory Box score
- Evidence of cerebral amyloid accumulation by either PET scan or CSF
-
If using cholinesterase inhibitors or memantine to treat symptoms related to AD, doses must be stable for at least three months (12 weeks) prior to Baseline and every attempt should be made to keep them at stable doses throughout the study
-
Must have a reliable informant or study partner who is willing and able to perform all the roles as specified in the study partner Informed Consent Form (ICF)
-
Female participants must be surgically sterile or be at least one-year post-menopausal. Male participants with a female partner of child-bearing potential must use adequate contraception
Exclusion Criteria:
-
Has any contraindications for MRI studies, including claustrophobia, the presence of metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with MRI
-
MRI of the brain that is inconsistent with MCI or AD or results showing greater than four ARIA-H, presence of any ARIA-E, or superficial siderosis
-
History of significant or unstable neurological disease, other than AD, which may affect cognition or ability to complete the study, such as other dementias, serious infection of the brain, significant head trauma, uncontrolled seizures, stroke, or Parkinson´s disease
-
Current serious or unstable clinically important illness that, in the judgment of the site investigator, is likely to affect cognitive assessment including visual and hearing impairment or affect the participant's safety or ability to complete the study
-
Malignant disease in the last five years except for resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal posttreatment prostate-specific antibody (PSA)
-
Geriatric Depression Scale-Short Form (GDS-SF) score >10 or current symptoms meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), criteria for major depressive disorder or any current primary psychiatric diagnosis other than AD if, in the judgment of the site investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the participant´s ability to complete the study
-
Suicide risk, as determined by meeting any of the following criteria:
- Any suicide attempt or preparatory acts/behavior on the C-SSRS Baseline/Screening in the last six months
- Suicidal ideation in the last six months as defined by a positive response to Question 5 (Suicidal Ideation) on the C-SSRS Baseline/Screening
- Significant risk of suicide, as judged by the site investigator
-
Conditions that may affect cognitive assessments during the study
-
Alcohol use disorder and/or substance use disorder within the last five years
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Double-blind Treatment (DBT) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 milligrams per kilogram (mg/kg), Q4W as intravenous (IV) infusion during the DBT period. |
Intravenous sabirnetug |
|
実験的:DBT Period: sabirnetug 50 mg/kg
Participants will receive sabirnetug, 35 mg/kg, for the first two doses, followed by sabirnetug, 50 mg/kg, Q4W as an IV infusion during the DBT period. |
Intravenous sabirnetug |
|
プラセボコンパレーター:DBT Period: Placebo
Participants will receive sabirnetug matching placebo, Q4W as an IV infusion during the DBT period. |
Intravenous Placebo |
|
実験的:Open-Label Extension (OLE) Period: sabirnetug 35 mg/kg
Participants will receive sabirnetug, 35 mg/kg, Q4W as an IV infusion during the OLE period. |
Intravenous sabirnetug |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score
時間枠:Baseline up to Week 80
|
iADRS is a validated composite of cognition and function made up of Alzheimer's Disease Assessment Scale - Cognitive Subscale 13-item (ADAS-Cog13) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living scale (ADCS-iADL). ADAS-Cog13 is a rater-administered instrument consisting of 13 items assessing cognitive function areas most typically impaired in AD. ADAS-Cog13 scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently. iADL-items score ranges from 0 to 59 (lower scores indicating greater impairment). The iADRS is calculated as a linear combination of total scores from the ADAS-Cog13 and ADCS-iADL. The iADRS score ranges from 0 to 144 with lower scores indicating worse performance. |
Baseline up to Week 80
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
治療関連有害事象(TEAE)のある参加者の数
時間枠:80週目までのベースライン
|
80週目までのベースライン
|
|
|
重篤な有害事象 (SAE) および特別な有害事象 (AESI) を有する参加者の数
時間枠:80週目までのベースライン
|
80週目までのベースライン
|
|
|
TEAEによる中止または撤退した参加者の数
時間枠:80週目までのベースライン
|
80週目までのベースライン
|
|
|
抗薬物抗体(ADA)および中和抗体を保有する参加者の数
時間枠:80週目までのベースライン
|
80週目までのベースライン
|
|
|
磁気共鳴画像法 (MRI) で測定した、浮腫/滲出液を伴うアミロイド関連画像異常 (ARIA-E) および出血/ヘモジデリン沈着を伴う ARIA (ARIA-H) を有する参加者の数
時間枠:80週目までのベースライン
|
80週目までのベースライン
|
|
|
参加者のサブセットにおける ACU193 の CSF 濃度
時間枠:76週目まで
|
76週目まで
|
|
|
センチロイド単位の陽電子放出断層撮影法 (PET) で測定したアミロイド斑の負荷または沈着のベースラインからの変化
時間枠:76週目までのベースライン
|
76週目までのベースライン
|
|
|
全脳容積、心室容積、および選択した関心領域の容積の容積磁気共鳴画像法 (vMRI) におけるベースラインからの変化
時間枠:76週目までのベースライン
|
76週目までのベースライン
|
|
|
アミロイド、タウおよびその他の神経変性バイオマーカーのCSF濃度のベースラインからの変化
時間枠:76週目までのベースライン
|
76週目までのベースライン
|
|
|
参加者のサブセットにおけるアミロイド、タウ、およびその他の神経変性バイオマーカーのCSF濃度のベースラインからの変化
時間枠:76週目までのベースライン
|
76週目までのベースライン
|
|
|
アミロイド、タウ、およびその他の神経変性バイオマーカーの血中濃度のベースラインからの変化
時間枠:76週目までのベースライン
|
76週目までのベースライン
|
|
|
IADRSで測定した時間節約分析を使用して評価した、プラセボと比較した臨床進行に対するセイビルネツグの効果
時間枠:80週目までのベースライン
|
80週目までのベースライン
|
|
|
ADCS-iADLで測定した時間節約分析を使用して評価した、プラセボと比較した臨床進行に対するsabirnetugの効果
時間枠:80週目までのベースライン
|
80週目までのベースライン
|
|
|
ADAS-Cog13で測定した時間節約分析を使用して評価した、プラセボと比較した臨床進行に対するセイビルネツグの効果
時間枠:80週目までのベースライン
|
80週目までのベースライン
|
|
|
CDR-SBによって測定された時間節約分析を使用して評価された、プラセボと比較した臨床進行に対するセイビルネツグの効果
時間枠:80週目までのベースライン
|
80週目までのベースライン
|
|
|
MMSEで測定した時間節約分析を使用して評価した、プラセボと比較した臨床進行に対するセイビルネツグの効果
時間枠:80週目までのベースライン
|
80週目までのベースライン
|
|
|
セイビルネツグの血清濃度
時間枠:最大80週間までの投与前および投与後の複数の時点
|
最大80週間までの投与前および投与後の複数の時点
|
|
|
脳脊髄液(CSF)中のセイビルネツグの濃度
時間枠:76週目まで
|
76週目まで
|
|
|
CSF中のサビルネツグ-アミロイド-βオリゴマー(AβO)複合体の測定による標的関与の評価
時間枠:76週目まで
|
76週目まで
|
|
|
Change from Baseline in ADCS-iADL Score
時間枠:Baseline up to Week 80
|
The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire to be answered by a participant's study partner, where a participant's performance level is rated over the last 4 weeks, based on a set of performance descriptions. The ADCS-iADL is a subset of the 23-item ADCS-ADL (items 6a and 7 to 23). The iADLs are more complex skills required to successfully live independently, and include shopping, keeping appointments, traveling outside of the home, making a meal or snack, and reading and writing. The iADL-items score ranges from 0 to 59 with lower scores indicating greater impairment. |
Baseline up to Week 80
|
|
Change from Baseline in ADAS-Cog13 Score
時間枠:Baseline up to Week 80
|
ADAS-Cog is a rater-administered instrument, designed to assess the severity of dysfunction in cognition, characteristic of persons with AD. The ADAS-Cog13, the cognitive subscale of the ADAS, consists of 13 items assessing cognitive function areas most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, and digit cancellation. The scores range from 0 to 85, with higher scores indicating a greater deficit of global cognition. |
Baseline up to Week 80
|
|
Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB)
時間枠:Baseline up to Week 80
|
The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Mini-Mental State Examination (MMSE)
時間枠:Baseline up to Week 80
|
MMSE is a standard staging and assessment tool in AD, designed for grading the cognitive state of individuals with AD. The scale comprises tasks concerning orientation, memory, attention, language, and praxis to evaluate an individual's cognitive state. MMSE total score ranges from 0 to 30, with lower scores indicative of greater cognitive impairment. |
Baseline up to Week 80
|
|
Change from Baseline in Quality of Life in Alzheimer's Disease (QoL-AD)
時間枠:Baseline up to Week 80
|
The QOL-AD tool is a 13-item assessment with each question scored on a 4-point scale where 1 = poor quality of life and 4 = excellent quality of life. Scores range from 13 to 52 with higher scores indicating better quality of life. |
Baseline up to Week 80
|
|
Change from Baseline in Neuropsychiatric Inventory Questionnaire (NPI-Q) Score
時間枠:Baseline up to Week 80
|
NPI-Q is a validated questionnaire completed by informants about participants for whom they care. Each of the 12 NPI-Q domains contains a survey question (answered in Yes/No) that reflects the cardinal symptoms of that domain. If the domain response is "Yes," the informant then rates the severity of the symptoms present within the last month on a 3-point scale and the distress of the symptom using a 5-point scale. The total NPI-Q severity score is the sum of the individual severity scores for each symptom and ranges from 0 to 36, with higher scores indicating more severe behavioral impairment. The total NPI-Q distress score is the sum of the individual distress scores for each symptom and ranges from 0 to 60, with higher scores indicating greater caregiver distress. |
Baseline up to Week 80
|
|
Change from Baseline in EuroQoL 5-Dimension 5-Level (EQ-5D-5L)
時間枠:Baseline up to Week 80
|
EQ-5D-5L is a self-report survey that measures quality of life. The EQ-5D-5L consists of an EQ-5D descriptive system and EQ visual analog scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels, each assigned a unique 1-digit number: no problems, slight problems, moderate problems, severe problems, and extreme problems. The digits are combined into a 5-digit number that describes the participant's health state. The EQ VAS records the participant's health on a vertical visual analog scale, where the endpoints are labeled 0= the best health you can imagine, and 100= the worst health you can imagine. |
Baseline up to Week 80
|
|
Change from Baseline in Resource Utilization in Dementia (RUD)
時間枠:Baseline up to Week 80
|
The RUD questionnaire is a standardized tool and the most widely used instrument for resource use data collection in dementia, enabling comparison of costs of care across countries with differing health care provisions. It is designed to collect data on formal and informal care resource use and to be useful in different care settings, across different countries and care systems, and in both clinical studies and observational cost-of-illness studies. |
Baseline up to Week 80
|
|
Change from Baseline in Zarit Burden Interview (ZBI)
時間枠:Baseline up to Week 80
|
ZBI consists of 22 items. Twenty-one of the items are designed to measure several aspects of burden, whereas Item 22 is a global measure of burden. Response options for each item range from 0-4, and total scores range from 0-88, with higher scores indicating greater self-reported burden. |
Baseline up to Week 80
|
|
Percentage of Participants with No Clinical Progression at One Year
時間枠:Baseline up to Week 80
|
No clinical progression in participants will be defined as no decline in CDR-SB score. The CDR is obtained through semi-structured interviews of individuals with AD and informants. The ratings are obtained in six domains: memory, orientation, judgment & problem-solving, community affairs, home & hobbies, and personal care. Each domain is rated on a five-point scale of functioning as follows: 0 = no impairment; 0.5 = questionable impairment; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. CDR-SB score is obtained by summing each of the domain scores, with scores ranging from 0 to 18. Higher scores reflect greater cognitive and functional impairment. |
Baseline up to Week 80
|
|
Number of Participants with Suicidal Ideation and Behavior as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
時間枠:Baseline up to Week 80
|
The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk. |
Baseline up to Week 80
|
|
Correlation Between sabirnetug Exposure with Clinical Efficacy Measures
時間枠:Baseline up to 80 weeks
|
Correlation between sabirnetug exposure and clinical outcomes (including iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) will be assessed in this study. |
Baseline up to 80 weeks
|
|
Correlation Between Change in Biomarker that Reflect Disease Progression and Clinical Changes
時間枠:Up to 80 weeks
|
Assessment of the correlation between change in clinical outcomes (iADRS, CDR-SB, ADCS-iADL, ADAS-Cog13, and MMSE) and change in biomarker (amyloid PET) will be determined by computing Pearson's correlation coefficient for each treatment group. |
Up to 80 weeks
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- ACU193-201
- 2023-509807-34-00 (レジストリ識別子:EU CT Number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。